World Pharma Week 2019

Screenshot 2019-06-12 17.54.58.png


Nicholas A. Geisse | Chief Science Officer, NanoSurface Biomedical

Alec S.T. Smith | Acting Instructor, University of Washington


hiPSC-CM maturation is sensitive to structural cues from the extracellular matrix (ECM). Failure to reproduce these signals in vitro can hamper experimental reproducibility and fidelity. Engineering approaches that address this gap typically trade off complexity with throughput, making them difficult to deploy in the modern drug development paradigm. The NanoSurface Car(ina)™ platform leverages ECM engineering approaches that are fully compatible with industry-standard instrumentation including HCI- and MEA-based assays, thereby improving their predictive power.

More from NanoSurface Biomedical - Booth 346


Title: Enhancing Pre-clinical In Vitro Safety, Efficacy, and Discovery Assays with Structurally-relevant iPSC-Cardiomyocyte Tissue Models in a High-throughput Manner

Presenting Author: Dr. Nicholas A. Geisse

Solutions Theatre 

Title: Structural Maturation in the Development of hiPSC-Cardiomyocyte Models for Pre-clinical Safety, Efficacy, and Discovery 

Presenting Author: Dr. Nicholas A. Geisse

Date: Thursday, June 20 – 10:15-10:45 AM

Heejoon ChoiComment